glp-1 for diabetic GLP-1R and Diabetes List of approved and pending
Description
ADM) and route of administration (oral vs
Add electrolyte supplementation
TAK-875, the best candidate for GPR40 which showed promising GSIS capabilities up to Clinical Phase III for the treatment of T2D, had to be halted because of hepatotoxicity and alteration of bile salts composition (290)
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
The safety analysis set was the same as the full analysis set
